Recent studies have centered on the convergence of GLP|glucose-dependent insulinotropic polypeptide|GCGR activator therapies and dopamine signaling. While GLP activators are widely employed for treating type 2 diabetes mellitus, their unexpected effects on reinforcement circuits, specifically mediated by dopaminergic networks, are gaining substa… Read More